Fig. 5.

Effect of miR-124 on M1 phase of microglia/macrophages. Photomicrographs show examples of double-staining immunofluorescence of CD16/32 and Iba-1 on brain sections of ischemic core and border zones acquired from three experimental groups at 6 days after stroke. Illustrative 4×, 20× - close-up magnifications visualize the changes in CD16/32 expression by Iba-1 positive cells (a-c). Scale bar: 50 μm. Time course for the CD16/32 expression by Iba-1+ cells in the ipsilateral and contralateral ROIs of cortex and striatum in miR-124 treated group compared to the only MCAO and negative control group at day 6 (d) and day 14 (e). Quantification results confirm that intracranial injection of miR-124 at day 2 after MCAO results in a significant decrease of Iba-1+ cells expressing CD16/32 monitored at day 6 post stroke (d). Representative graph shows no differences at CD16/32 expression by Iba-1+ cells at day 14 after stroke between groups (e). n = 5–6 mice in each group and for each time point. *P < 0.05, **P < 0.01 at one-way ANOVA (with Bonferroni’s post hoc test). Scale bar 50 μm